Preclinical studies from our laboratory demonstrated that activation of PPARγ in human non-small cell lung cancer cell (NSCLC) lines inhibited transformed growth and invasiveness, and promoted a more differentiated phenotype [10], [11]. The gene discussed is PPARG; the disease is non-small cell lung carcinoma.